thedeepdive2d
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
A Controversial Alzheimer’s Drug Has Gone Down in Flames
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...
Hosted on MSN2d
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 83.9% over the past four weeks. However, given the fact that it is now in ...
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its ...
FierceBiotech3d
Cassava flunks phase 3 Alzheimer's test, triggering early end of 2nd trial and stock crash
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...
ATTENTION SAVA SHAREHOLDERS: Investors who Lost Money on Cassava Sciences, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...